Corporate Banner
Satellite Banner
Cell Culture
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sartorius Stedim Announces Offer to Acquire TAP Biosystems

Published: Tuesday, October 08, 2013
Last Updated: Tuesday, October 08, 2013
Bookmark and Share
Sartorius Stedim Biotech to further expand its portfolio of single-use fermentors.

Sartorius Stedim Biotech has made a cash offer to acquire the UK company TAP Biosystems Group plc (TAP Biosystems) through its wholly owned subsidiary Sartorius Stedim Biotech GmbH.

The proposed transaction, which is subject to customary closing conditions, including the approval of TAP’s shareholders, values the equity of TAP Biosystems at approximately €33 million.

The transaction has been unanimously approved by the boards of directors of both companies and is expected to close at the end of 2013.

In making the announcement, Joachim Kreuzburg, the Chief Executive of Sartorius Stedim Biotech, stated, “TAP Biosystems’ fermentors are a great fit extending our reach into the small scale cell culture applications. Adding capabilities in the early steps of upstream bioprocessing will enable us to provide our biopharma customers highly effective and scalable solutions to accelerate cell line selection, speed-up process development and ultimately help them bringing their biologics to market faster”.

TAP Biosystems plc specializes in the design and development of small-scale, multi-parallel fermentation systems particularly for biopharmaceutical applications.

With its ambr®-product family, the company has launched a novel platform technology for single-use fermentation that is designed to mimic mammalian cell culture at small scale, a highly innovative alternative to conventional systems.

Furthermore TAP Biosystem’s portfolio includes automated cell processing systems and other bench top equipment.

Founded in 1987, the company is headquartered in Royston, UK, and has a sales and support facility near Wilmington, Delaware, USA. TAP Biosystems generated sales revenue of approx. €26 million in 2012/13 and employs about 160 people worldwide.

Welcoming the acquisition, David Newble, CEO of TAP Biosystems, said, “As a market leader in bioprocessing technologies with a strong position in fermentation, Sartorius Stedim Biotech is well-placed to maximize the opportunities of our novel, highly innovative cell culture technologies. We look forward to joining such a well-recognized organization as Sartorius Stedim that will enable us to grow our business further with a wealth of complementary technologies and products”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sartorius Stedim Biotech and GE Healthcare Sign Worldwide OEM Supply Agreement
Expands GE’s start-to-finish offering for cost efficient manufacture of biopharmaceuticals.
Tuesday, September 01, 2015
Scientific News
‘Mini-Brains’ to Study Zika
Novel tool expected to speed research on brain and drug development.
Cytokine Triggers Immune Response at Expense of Blood Renewal
Research highlights promise of Anti-IL-1 drugs to treat chronic inflammatory disease.
Micro Heart Muscle Created from Stem Cells
Researchers have designed a new way to create micro heart muscle from stem cells using a unique dog bone dish.
“Secret Sauce” for Personalized, Functional Insulin-producing Cells
Researchers uncover molecular switch to make effective sugar-responsive, insulin-releasing cells in a dish, offering hope for diabetes therapy.
Insights into Early Human Embryo Development
Researchers at Karolinska Institutet and the Ludwig Cancer Research in Stockholm have conducted a detailed molecular analysis of the embryo’s first week of development.
Boosting Gene Transfer Capabilities
A new and highly efficient method for gene transfer has been developed.
Liver-On-Chip Tracks Dynamics of Cellular Function
Hebrew University’s liver-on-chip platform is uniquely able to monitor metabolic changes indicating mitochondrial damage occurring at drug concentrations previously regarded as safe.
EU Project Aims to Cure Type 1 Diabetes
Researchers develop organoids from insulin-producing cells for transplantation.
Hope for Combating Muscular Dystrophy
Decoding a sugar molecule and identifying a mechanism linking it to MS could help in the development of therapy for the disease.
Decoding Sugar Molecules Offers New Key For Combating Muscular Dystrophy
Japanese scientists find a rare sugar unit called ribitol 5-phosphate within the sugar molecules on the surface of muscle cells. Mutations in 3 genes linked to muscular dystrophy affect the creation of this sugar molecule.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!